The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM
Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, discusses the debate between fixed-duration and continuous BTK inhibitor (BTKi) treatment in Waldenström’s macroglobulinemia and other malignancies. He advocates for fixed-duration therapy due to the issue of cumulative toxicities associated with continuous administration of BTKis and suggests that measurable residual disease (MRD) could be used to guide treatment discontinuation. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Смотрите видео The potential of fixed-duration BTKis and using MRD to guide treatment discontinuation in WM онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 24 Октябрь 2024, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 120 раз и оно понравилось 1 людям.